Are All COX-2s Created Equal? Merck, Pfizer Weigh In
This article was originally published in The Tan Sheet
Executive Summary
Merck and Pfizer appear to be somewhat at odds over whether cardiovascular signals in Vioxx and Celebrex studies signify a broad COX-2 inhibitor class effect